Pitanium (Nasdaq: PTNM) launches Pi-ology and Pi-Formance wellness series
Rhea-AI Filing Summary
Pitanium Limited is introducing two new personal care product lines under its Pitanium brand while addressing the status of a trading halt in its securities. The Pi-ology Series uses biotechnological skincare and fermentation techniques to enhance ingredient activity, purity, stability, penetrability, and longevity, aiming to improve skin compatibility and deeper nutrient delivery. The Pi-Formance Series focuses on internal wellness, with targeted supplements such as women’s probiotics and hair follicle health formulas designed to strengthen the body from within and complement skincare benefits. The company states that these products will roll out gradually and emphasizes that product descriptions are not medical claims. Separately, Pitanium reports it has submitted responses and supporting materials to Nasdaq’s latest information requests and has responded to all comments and document requests from the SEC, Nasdaq, and FINRA. The company notes that business operations remain normal and uninterrupted as of the report date.
Positive
- None.
Negative
- None.
Insights
Pitanium adds wellness lines while addressing an ongoing trading halt.
Pitanium Limited introduces its Pi-ology biotechnological skincare line and Pi-Formance internal wellness supplements, signaling continued product development in both topical and ingestible personal care. The dual "external care and internal health" positioning aims to link skincare with broader wellness.
The company also updates investors on the existing trading halt of its securities. It reports having responded to all information and document requests from the SEC, Nasdaq, and FINRA, and submitted new materials to Nasdaq on April 20, 2026 and May 4, 2026. Business operations are described as normal and uninterrupted, but the filing does not indicate any decision on resuming trading.
Key Figures
Key Terms
forward-looking statements regulatory
trading halt regulatory
biotechnological skincare financial
probiotics other
supplements other
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2026
Commission File Number: 001-42669
PITANIUM LIMITED
(Registrant’s Name)
30F, Gravity, 29 Hing Yip Street,
Kwun Tong, Kowloon, Hong Kong
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
CONTENTS
Press Release
On May 4 , 2026, Pitanium Limited (the “Company”) issued a press release, which was published on its official website, announcing the gradual introduction of two new product lines under its Pitanium brand. A copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K.
Forward-Looking Statements
The press release may contain forward-looking statements. Certain statements are not historical facts, and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance and financial results. These statements include, but are not limited to, statements regarding the expected launch, availability, and potential benefits of the Company’s new product lines. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in such statements. These risks and uncertainties include, among others, changes in market conditions, regulatory developments, product development and commercialization risks. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by applicable law.
Update on Trading Halt of Securities and Company Responses
Reference is made to the Company’s Reports on Form 6-K furnished on October 31, 2025 and November 21, 2025, which disclosed the trading halt of the Company’s securities, related information requests, and the Company’s written responses thereto.
On April 20, 2026, the Company received additional information requests from The Nasdaq Stock Market (Nasdaq) for certain information and documents, and the Company submitted its written response with supporting materials to Nasdaq on May 4, 2026. As of the date of this report, the Company has responded to all comments and document requests received from the U.S. Securities and Exchange Commission (SEC), Nasdaq, Financial Industry Regulatory Authority (FINRA), as applicable. The Company continues to monitor the matter and remains committed to cooperating in a transparent and timely manner. The Company’s business operations remain normal and uninterrupted as of the date of this report.
This Report on Form 6-K and the information contained herein shall be deemed to be furnished and not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
EXHIBIT INDEX
| Exhibit No. | ||
| 99.1 | Press Release Dated May 4, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Date: May 5, 2026 | PITANIUM LIMITED | |
| By: | /s/ Ying Yeung Wong | |
| Name: | Ying Yeung Wong | |
| Title: | Chief Executive Officer and Director | |
Exhibit 99.1
Pitanium’s All-New Series Debut:
Pi-ology and Pi-Formance Offer a New Approach for Inside-Out Care
HONG KONG, China, May 4, 2026 — PITAMIUM LIMITED (Nasdaq: PTNM) introduces two major new product lines: the Pi-ology Series, which focuses on biotechnological skincare, and the Pi-Formance Series, dedicated to body function and wellness. Through the dual synergistic effect of “external care and internal health,” Pitanium aims to enhance personal care and anti-aging management.
(Source: Pitanium Limited)
The Pi-ology Series: Biotechnological Skincare
This series applies advanced biotechnology and ingredient fermentation techniques to the realm of skincare. Through fermentation processes, core ingredients undergo a profound transformation, offering certain benefits:
Five-Dimensional Enhancement: The activity, purity, stability, penetrability, and longevity of the ingredients are enhanced.
Improved Skin Compatibility: The fermented molecular structure is designed to support skin affinity. Nutrients are expected to reach the deeper layers of the skin with “zero rejection,” exerting the purest and most highly effective skincare benefits.
The Pi-Formance Series: Building a Healthy Constitution from Within
The Pi-Formance Series is expected to introduce targeted supplements, including women’s probiotics and hair follicle health formulas. Through internal wellness support, Pitanium aims to comprehensively fortify the body’s foundation. This empowers individuals to navigate daily challenges with optimal health and vitality, while simultaneously creating a powerful synergy with our skincare lines to support overall health and complement daily routines.
By combining the skincare technology of Pi-ology with the robust physiological support of Pi-Formance, Pitanium brings together dermatological science with biological wellness. The new product lines will be rolling out soon, inviting all users to step into a new era of personal care together.
The statements above are intended to describe product features and are not intended as medical or therapeutic claims. Results may vary among individuals.